Paul Grayson Biography and Net Worth

Director of Skye Bioscience

Mr. Grayson serves as Chief Executive Officer of Radionetics. He has been focusing on company origination, platform validation, IND enablement, and large and small molecule CMC through clinical proof of concept across a broad range of technologies and applications as both a CEO and a Venture Partner over the past 25 years. He was most recently the President and CEO of Tentarix Biotherapeutics, an oncology company focused on multi-functional biologics. His previous experiences also include founding roles at BirdRock Bio (acquired by Skye Biosciences), Fate Therapeutics (NASDAQ: FATE), Senomyx (acquired by Firmenich), and Aurora Biosciences (acquired by Vertex Pharmaceuticals).

What is Paul A. Grayson's net worth?: The estimated net worth of Paul A. Grayson is at least $71.35 thousand as of November 15th, 2024. Mr. Grayson owns 43,243 shares of Skye Bioscience stock worth more than $71,351 as of October 8th. This net worth estimate does not reflect any other assets that Mr. Grayson may own. Learn More about Paul A. Grayson's net worth.
How do I contact Paul A. Grayson?: The corporate mailing address for Mr. Grayson and other Skye Bioscience executives is 11250 EL Camino Real, Suite 100, San Diego, CA, 92130. Skye Bioscience can also be reached via phone at 858-410-0266 and via email at [email protected]. Learn More on Paul A. Grayson's contact information.
Has Paul A. Grayson been buying or selling shares of Skye Bioscience?: Paul A. Grayson has not been actively trading shares of Skye Bioscience in the last ninety days. Most recently, Paul A. Grayson sold 10,780 shares of the business's stock in a transaction on Monday, November 18th. The shares were sold at an average price of $39.92, for a transaction totalling $430,337.60. Following the completion of the sale, the director now directly owns 32,462 shares of the company's stock, valued at $1,295,883.04. Learn More on Paul A. Grayson's trading history.
Who are Skye Bioscience's active insiders?: Skye Bioscience's insider roster includes Punit Dhillon (CEO), Paul Grayson (Director), and Andrew Schwab (Director). Learn More on Skye Bioscience's active insiders.
Are insiders buying or selling shares of Skye Bioscience?: In the last twelve months, insiders at the sold shares 12 times. They sold a total of 457,900 shares worth more than $889,198.46. The most recent insider tranaction occured on September, 23rd when Director Andrew J. Schwab sold 119,379 shares worth more than $192,200.19. Insiders at Skye Bioscience own 6.2% of the company. Learn More about insider trades at Skye Bioscience.
Information on this page was last updated on 9/23/2026.

Paul A. Grayson Insider Trading History at Skye Bioscience

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/18/2024	Sell	10,780	$39.92	$430,337.60	32,462
11/15/2024	Sell	38	$44.40	$1,687.20	43,243

Paul A. Grayson Buying and Selling Activity at Skye Bioscience

Skye Bioscience Company Overview

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Today's Range

Now: $1.66

$1.66

$1.69

50 Day Range

MA: $2.50

$1.57

$4.67

2 Week Range

Now: $1.66

$1.50

$14.08

Volume

7,912 shs

Average Volume

61,237 shs

Market Capitalization

$7.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.86